Vetter Offers Answers for the Future at the Pharma Congress 2013
News Feb 19, 2013
Changing markets and potential solutions will be the highlight at the 15th Pharma Congress Production & Technology in Duesseldorf, Germany, March 19 - 20. Vetter, one of the worlds’ leading Contract and Development Manufacturing Organization, will present on a variety of informative core developments critical to the international pharmaceutical and biotech industries. Udo J. Vetter, chairman of the Vetter advisory board, will present the keynote address at the Congress focusing his comments on the future demands and challenges in pharmaceutical manufacturing. Vetter experts will address various topics including the needs for filling monoclonal antibodies, advantages and solutions of restricted access barrier systems (RABS) and the implementation of isolators for sterility tests as well as Vetter’s own supplier management system and the company’s new Center for Visual Inspection and Logistics.
Major changes taking place among the world’s leading pharmaceutical and biotech companies demand creative solutions to complex challenges by the manufacturing industry. The 15th Pharma Congress Production & Technology held in mid-March, will bring together representatives from the private and public sectors to discuss the current market trends. Vetter, an international specialist in aseptic filling, will present on best practices in sterile manufacturing and packaging.
Presenter and topics include Udo J. Vetter, who will be focusing on aseptic manufacturing at the Congress's keynote. The chairman of the Vetter advisory board will be speaking about the current market trends and their long-term effects on sterile production. He will also discuss changing technological and regulatory requirements and how innovative and flexible production plants can provide answers.
Joerg Zimmermann, Director Process Development and Implementation will present two case studies including Vetter’s experiences with fill-and-finish considerations for monoclonal antibodies and how certain challenges are already being met in the early phases. His second case study will cover the function and advantages of the restricted access barrier systems (RABS) in aseptic manufacturing and how to operate a RABS-based line successfully based on real life experience. Mr. Zimmermann will also moderate the ECA Barrier Systems Conference, one of the key sessions of the Congress.
Dr. Andreas Reicke, Team Coordinator at Vetter’s microbiology division will review a case study on the implementation of sterility test isolators. He will talk about regulatory demands and considerations in regards to design, location and utilities as well as project planning from beginning through to implementation.
Uli Kuchenbrod, Director Incoming Goods at Vetter, will give his insights into Vetter‘s supplier management system and incoming inspections as part of quality control. He will also address the operative challenges as well as the strategic considerations between a CDMO and its suppliers.
Thomas Ruebekeil, Director Investment Projects will introduce the new Vetter Ravensburg site. He will present the project plan and best practice as well as provide an update on the Center for Visual Inspection and Logistics including characteristics of the building itself and the use of regenerative energy and how it can be safely and efficiently used in the pharmaceutical sector.
All of the presentations are consistent with the goal of the international event which is to present lectures as technical applications "from users for users", primarily concentrating on their practical benefits.
Radical New Approach to Vaccine Development Could Help Reduce Illness From FluNews
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help lower that figure for future flu seasons.READ MORE
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.